|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,898.30 INR | -2.41% |
|
-2.14% | +27.23% |
| 07-16 | Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges | RE |
| 07-09 | India's Dr Reddy's says semaglutide shipping disruption to last until at least late October | RE |
| Market Cap | 1,864B 19.44B 17.07B 15.92B 14.63B 27.43B 27.88B 188B 73.76B 921B 72.99B 71.41B 3,187B | P/E 2027 * |
70.8x | P/E 2028 * | 52.2x |
|---|---|---|---|---|---|
| Enterprise Value | 1,978B 20.64B 18.12B 16.9B 15.53B 29.12B 29.59B 200B 78.29B 978B 77.47B 75.8B 3,382B | EV / Sales 2027 * |
10.4x | EV / Sales 2028 * | 9.09x |
| Free-Float |
36.66% | Yield 2027 * |
0.62% | Yield 2028 * | 0.7% |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | -2.41% | ||
| 1 week | -2.14% | ||
| Current month | +6.02% | ||
| 1 month | +8.46% | ||
| 3 months | +16.08% | ||
| 6 months | +22.54% | ||
| Current year | +27.23% |
| 1 week | 4,866 |  | 5,078.5 |
| 1 month | 4,506.1 | | 5,085.8 |
| Current year | 3,695 | | 5,085.8 |
| 1 year | 3,480.6 | | 5,085.8 |
| 3 years | 1,772.05 | | 5,085.8 |
| 5 years | 1,242.08 | | 5,085.8 |
| 10 years | 570.98 | | 5,085.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 2025-07-31 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 2018-08-31 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 2026-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 2014-07-29 | |
| Director/Board Member | 46 | 2018-02-07 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 2019-03-06 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.41% | -2.14% | - | - | 19.9B | |
| +1.93% | +6.43% | +50.20% | +168.28% | 1,068B | |
| +0.29% | +7.20% | +58.48% | +53.57% | 641B | |
| +2.45% | +3.88% | +38.32% | +76.82% | 454B | |
| +2.17% | +10.91% | +41.94% | +35.03% | 351B | |
| +1.46% | +5.93% | +40.44% | +43.69% | 299B | |
| +0.40% | +4.52% | +19.79% | +20.93% | 266B | |
| +2.73% | +2.26% | -25.81% | -36.98% | 220B | |
| +4.48% | +7.94% | +28.22% | +66.53% | 203B | |
| +2.91% | +0.83% | +15.59% | +75.56% | 162B | |
| Average | +0.85% | +2.76% | +29.69% | +55.94% | 407.04B | |
| Weighted average by Cap. | +0.77% | +2.85% | +39.07% | +81.20% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 190B 1.99B 1.74B 1.63B 1.5B 2.8B 2.85B 19.25B 7.54B 94.13B 7.46B 7.3B 326B | 214B 2.23B 1.96B 1.83B 1.68B 3.15B 3.2B 21.63B 8.47B 106B 8.38B 8.2B 366B |
| Net income | 24.86B 259M 228M 212M 195M 366M 372M 2.51B 984M 12.29B 974M 953M 42.51B | 33.98B 355M 311M 290M 267M 500M 508M 3.43B 1.34B 16.79B 1.33B 1.3B 58.1B |
| Net Debt | 114B 1.19B 1.05B 977M 898M 1.68B 1.71B 11.56B 4.53B 56.53B 4.48B 4.38B 196B | 82.03B 856M 752M 701M 644M 1.21B 1.23B 8.29B 3.25B 40.54B 3.21B 3.14B 140B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-28 | ₹4,898.30 | -2.41% | 549,152 |
| 26-07-27 | ₹5,019.50 | +1.17% | 267,708 |
| 26-07-24 | ₹4,961.50 | -2.05% | 262,189 |
| 26-07-23 | ₹5,065.20 | +0.63% | 423,979 |
| 26-07-22 | ₹5,033.40 | -0.14% | 290,320 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TORNTPHARM Stock
- TORNTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
